What is Lexicon Pharmaceuticals's SG&A?

Lexicon Pharmaceuticals (LXRX) reported SG&A of $9.23M in Q1 2026.

How has Lexicon Pharmaceuticals's SG&A changed year-over-year?

Lexicon Pharmaceuticals's SG&A decreased by 20.5% year-over-year, from $11.61M to $9.23M.

What is the long-term trend for Lexicon Pharmaceuticals's SG&A?

Over 3 years (2021 to 2025), Lexicon Pharmaceuticals's SG&A has grown at a 4.9% compound annual growth rate (CAGR), from $32.34M to $37.32M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Lexicon Pharmaceuticals LXRX SG&A

SG&A at other companies

Eli LillyLLY

$2.93B+18.9%

PfizerPFE

$2.96B-2.3%

Merck & Co.MRK

$2.7B+5.8%

Vertex PharmaceuticalsVRTX

$493.7M+24.5%

Zevra Therapeutics, Inc.ZVRA

$20.78M+6.3%

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$986.12M+273%

Enterprise value$976.73M+219%

P/S14.2×+5.7×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's SG&A?: Lexicon Pharmaceuticals (LXRX) reported SG&A of $9.23M in Q1 2026.
How has Lexicon Pharmaceuticals's SG&A changed year-over-year?: Lexicon Pharmaceuticals's SG&A decreased by 20.5% year-over-year, from $11.61M to $9.23M.
What is the long-term trend for Lexicon Pharmaceuticals's SG&A?: Over 3 years (2021 to 2025), Lexicon Pharmaceuticals's SG&A has grown at a 4.9% compound annual growth rate (CAGR), from $32.34M to $37.32M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.